U.S. Court of Appeals for the Federal Circuit Affirms Merus' Inequitable Conduct Claim Against Regeneron
UTRECHT, The Netherlands, July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), today announced that the U.S. Court of Appeals for the Federal Circuit affirmed the trial court's conclusion that Regeneron Pharmaceuticals, Inc. engaged in inequitable conduct before the United States Patent and Trademark Office while prosecuting U.S. Patent No. 8,502,018 ('018 patent), entitled "Methods of Modifying Eukaryotic Cells."
In today's decision, the Federal Circuit ruled fully in favor of Merus, affirming that Regeneron's '018 patent is unenforceable, having been obtained by inequitable conduct. The Federal Circuit noted Regeneron made "false" assertions, relied on a "misleading presentation," and withheld material information from the United States Patent Office, and further, that Regeneron's "litigation misconduct" "obfuscated its prosecution misconduct."
"We are pleased by today's decision, which serves as the latest vindication for Merus in this case against Regeneron," said Ton Logtenberg, Ph.D., Chief Executive Officer of Merus. "With this decision, and based on the continued strength of our IP estate, Merus remains focused and believes it is well-positioned as an innovator in the development of full-length human bispecific antibody therapeutic candidates for serious diseases."
About Merus N.V.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to have several of the same features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is expected to begin a Phase 2 clinical trial in the second half of 2017 in two metastatic breast cancer populations. MCLA-128 is also being evaluated in a Phase 1/2 clinical trial in Europe in gastric, ovarian, endometrial and non-small cell lung cancers. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as MCLA-145 designed to bind to PD-L1 and a non-disclosed second immunomodulatory target, which is being developed in collaboration with Incyte Corporation.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.
These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our need for additional funding, which may not be available and which may require us to restrict our operations or require us to relinquish rights to our technologies or Biclonics® and bispecific antibody candidates; potential delays in regulatory approval, which would impact our ability to commercialize our product candidates and affect our ability to generate revenue; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; the unpredictable nature of our early stage development efforts for marketable drugs; potential delays in enrollment of patients, which could affect the receipt of necessary regulatory approvals; our reliance on third parties to conduct our clinical trials and the potential for those third parties to not perform satisfactorily; we may not identify suitable Biclonics® or bispecific antibody candidates under our collaboration with Incyte or Incyte may fail to perform adequately under our collaboration; our reliance on third parties to manufacture our product candidates, which may delay, prevent or impair our development and commercialization efforts; our ability to protect our proprietary technology; our patents may be found invalid, unenforceable, circumvented by competitors and our patent applications may be found not to comply with the rules and regulations of patentability; we may fail to prevail in existing and potential lawsuits for infringement of third-party intellectual property; and our registered or unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on other marks.
These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 20-F filed with the Securities and Exchange Commission, or SEC, on April 28, 2017, and our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change, except as required under applicable law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
+1 973 361 1546
+1 646 368 8014
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Merus N.V. via Globenewswire
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Kalmar and Tropical Shipping strengthen long-term relationship with new order for straddle carriers15.8.2022 09:00:00 CEST | Press release
CARGOTEC CORPORATION, PRESS RELEASE, 15 AUGUST 2022 AT 10 AM (EEST) Kalmar, part of Cargotec, has concluded an agreement to supply international cargo and logistics operator Tropical Shipping with three Kalmar diesel-electric straddle carriers. The order was booked in Cargotec's 2022 Q3 order intake, and the delivery of all units is scheduled to be completed in Q3 2023. Part of the Saltchuk family of companies, Tropical Shipping is a leader in quality, on-time transportation solutions. From Canada to South Florida and the U.S. Virgin Islands, the company operates state-of-the-art facilities in selected seaside ports to meet the customers’ freight-shipping needs to and from the Caribbean and the Bahamas. Tropical Shipping operates a large fleet of Kalmar equipment including straddle carriers, reachstackers and terminal tractors. The Kalmar Straddle Carrier is powered by a diesel-electric driveline and offers high performance, excellent fuel efficiency and low noise as well as complying
Hoylu AB: Continued SaaS growth in July15.8.2022 08:30:00 CEST | Press release
Stockholm, Sweden, August 15, 2022 – Hoylu, a leader in visual collaboration solutions for distributed teams, today announced Annual Recurring Revenue (“ARR”) as of the end of July 2022. ARR, including long term mobile contracts, reached MSEK 48.5 as of the end of July 2022, up from MSEK 46.2 as of the end of June 2022. The report for July 2022 is attached to this press release and is available on Hoylu's web site: (https://www.hoylu.com/investor-relations/financial-reports/). For more information, please contact: Truls Baklid, CEO, +47 924 38 900 Email: firstname.lastname@example.org Karl Wiersholm, CFO, +1 425 829 2316 Email: email@example.com About Hoylu Hoylu's Adaptive Workspace opens up a new way for teams to plan, build and engage --so they get the impact they want no matter the industry, department or time. Whatever your management or planning style, Hoylu fits the way you structure your team and integrates all the productivity tools you're already using. So, you easily plan and complete any project
Expereo acquires Breeze Networks, further enhancing its SD-WAN/SASE practice and presence in the UK market15.8.2022 08:00:00 CEST | Press release
AMSTERDAM, Aug. 15, 2022 (GLOBE NEWSWIRE) -- The world’s leading provider of managed network solutions, Expereo, has announced the acquisition of Breeze Networks, a managed service provider of SD-WAN/SASE technologies. The acquisition fuels Expereo’s growth trajectory, further enhancing its SD-WAN/SASE practice, building on its expanding range of services to manage SD-WAN solutions at scale to partners and multinational enterprise customers across the globe. This latest acquisition solidifies Expereo’s ambition to complement its managed network solutions with world-class advisory practice providing guidance to organizations on their global transformation to software-defined and internet-based networking. With the full support of majority investor Vitruvian Partners and minority investor Apax Partners SAS, Expereo intends to continue its acquisition strategy. Breeze Networks is a managed service provider of cloud-based (SD-WAN) network connectivity and security solutions for enterprises
DNO Releases 2021 Corporate Social Responsibility Report15.8.2022 08:00:00 CEST | Press release
Oslo, 15 August 2022 – DNO ASA, the Norwegian oil and gas operator, today released its 2021 Corporate Social Responsibility Report. The report is attached as a downloadable file and is also available on the Company's website www.dno.no. – For further information, please contact: Media: firstname.lastname@example.org Investors: email@example.com – DNO ASA is a Norwegian oil and gas operator focused on the Middle East and the North Sea. Founded in 1971 and listed on the Oslo Stock Exchange, the Company holds stakes in onshore and offshore licenses at various stages of exploration, development and production in the Kurdistan region of Iraq, Norway, the United Kingdom, Netherlands and Yemen. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. Attachment 2021 CSR report
Sampo plc’s share buybacks 12/08/202215.8.2022 07:30:00 CEST | Press release
SAMPO PLC STOCK EXCHANGE RELEASE 15/08/2022 at 08:30 am Sampo plc’s share buybacks 12/08/2022 On 12/08/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)14,42245.06AQEU29,72844.98CEUX9,01645.09TQEX76,83445.02XHELTOTAL130,00045.02 *rounded to two decimals On 9 June 2022, Sampo announced a share buyback programme of up to a maximum of EUR 1 billion in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 10 June 2022, is based on the authorization granted by Sampo's Annual General Meeting on 18 May 2022. After the disclosed transactions, the company owns in total 6,194,495 Sampo A shares representing 1.16 per cent of the total number of shares in Sampo plc. Details of ea